Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the ...

A phase 2 trial of Avalo Therapeutics’ hidradenitis suppurativa (HS) candidate hit its primary endpoint, emboldening the ...

Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of ...

Gilead will lay off 108 workers from Arcellx’s site at 800 Bridge Parkway in Redwood City, CA, according to a Worker ...

Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like it will ever pay out, with the Big Pharma abandoning the ...

A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to ...

Olympus has inked a collaboration deal for the global distribut | Olympus inked a collaboration deal for the global ...

Roche’s Foundation Medicine has linked with Fulgent Genetics to offer a new diagnostic test that identifies a person’s ...

After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals ...

After some tough feedback from the FDA on the path forward for its lead gene therapy, Passage Bio has launched a strategic ...

UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merger with Rallybio ...